Inicio › Cáncer de seno › Georgia

Ensayos clínicos de Cáncer de seno en Georgia

52 estudios sobre Cáncer de seno buscan participantes en Georgia.

Ciudades en Georgia

Texto oficial del estudio (inglés)

A Study Evaluating the Safety of Inavolisib and Fulvestrant With or Without Palbociclib in Participants With Advanced Breast Cancer (ABC) and Type 2 Diabetes

Grady Memorial Hospital, Atlanta
Emory University Hospital Midtown, Atlanta
Emory University Hospital, Atlanta

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 13 nov 2026 · NCT07748208

Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

Emory University School of Medicine, Atlanta

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 13 nov 2026 · NCT05696626

A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer

University Cancer & Blood Center, LLC, Athens
Summit Cancer Care, Savannah

ReclutandoFase 1

Edades de 18 a 55 · Mujeres · Actualizado el 12 nov 2026 · NCT07310420

S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity

Emory University Hospital/Winship Cancer Institute, Atlanta
Northside Hospital, Atlanta
Northeast Georgia Medical Center-Gainesville, Gainesville
y 2 más

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 12 nov 2026 · NCT03418961

Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.

Research Facility, Atlanta

ReclutandoFase 1/2

Todas las edades · Todos los sexos · Actualizado el 12 nov 2026 · NCT06590857

A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer

University Cancer & Blood Center, LLC, Athens
Winship Cancer Institute of Emory University, Atlanta

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 10 nov 2026 · NCT06827236

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

City of Hope Cancer Center - Atlanta ( Site 0102), Newnan

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 10 nov 2026 · NCT06966700

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

Atlanta Cancer Care - Northside Hospital, Atlanta

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 5 nov 2026 · NCT06982521

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

University Cancer & Blood Center, LLC, Athens
Piedmont Columbus Regional - John B. Amos Cancer Center, Columbus
Central Georgia Cancer Care, Macon
y 3 más

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 4 nov 2026 · NCT07174336

A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

Northwest Georgia Oncology Centers PC - Marietta, Marietta

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 4 nov 2026 · NCT06790693

E-Mindfulness Approaches for Living After Breast Cancer

Grady Health System, Atlanta
Emory University Hospital Midtown, Atlanta
Emory University Hospital/Winship Cancer Institute, Atlanta
y 4 más

ReclutandoFase 3

Edades de 18 a 50 · Todos los sexos · Actualizado el 4 nov 2026 · NCT06748222

A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer

Winship Cancer Institute, Atlanta
City of Hope National Medical Center, Atlanta Cancer Center, Newnan

ReclutandoFase 2

Edades de 18 en adelante · Mujeres · Actualizado el 4 nov 2026 · NCT07287098

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Northeast Georgia Medical Center Braselton, Braselton
Atlanta VA Medical Center, Decatur
Northeast Georgia Medical Center-Gainesville, Gainesville
y 4 más

ReclutandoEstudio observacionalSe aceptan voluntarios sanos

Edades de 40 a 75 · Todos los sexos · Actualizado el 4 nov 2026 · NCT05334069

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

Augusta University Georgia Cancer Center, Augusta

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 4 nov 2026 · NCT05579366

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

Northside Hospital, Atlanta
John B Amos Cancer Center, Columbus
Northside Hospital - Duluth, Duluth
y 5 más

ReclutandoEstudio observacional

Edades de 18 en adelante · Todos los sexos · Actualizado el 4 nov 2026 · NCT06418204

A Study of Sofe-M in Participants With Selected Advanced Solid Tumors

Emory University, Atlanta

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 4 nov 2026 · NCT06400472

A Study of LY4257496 in Participants With Cancer (OMNIRAY)

Emory University School of Medicine - Winship Cancer Institute, Atlanta

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 4 nov 2026 · NCT07114601

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

Phoebe Putney Memorial Hospital, Albany
University Cancer and Blood Center LLC, Athens
Grady Health System, Atlanta
y 17 más

ReclutandoFase 3

Edades de 18 a 60 · Mujeres · Actualizado el 4 nov 2026 · NCT05879926

The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study

Emory University Winship Cancer Institute, Atlanta
Liberty County Cancer Care, Hinesville
Pembroke Medical Oncology & St Joseph's/Candler Oncology Infusion Suite, Pembroke
y 2 más

ReclutandoFase 3

Edades de 60 en adelante · Todos los sexos · Actualizado el 2 nov 2026 · NCT06377852

Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

Emory University, Atlanta

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 29 oct 2026 · NCT07288359

A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy

Emory University Hospital, Atlanta

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 26 oct 2026 · NCT05646862

A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer

Winship Cancer Institute of Emory University, Atlanta

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 26 oct 2026 · NCT07100106

Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma

Emory University - Winship Cancer Institute, Atlanta

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 20 oct 2026 · NCT06582017

A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer

Research Site, Marietta

ReclutandoFase 3

Edades de 18 a 130 · Todos los sexos · Actualizado el 19 oct 2026 · NCT07647328

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

Emory University Hospital Midtown, Atlanta
Emory University Hospital, Atlanta
Investigational Drug Service Emory University Clinic, Atlanta
y 4 más

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 19 oct 2026 · NCT07062965

Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

Georgia Cancer Center at Augusta University, Augusta

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 13 oct 2026 · NCT06293898

A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer

Winship Cancer Institute, Emory University, Atlanta

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 1 oct 2026 · NCT06369285

Conventionally Fractionated vs. Hypofractionated Comprehensive Nodal Irradiation for Breast Cancer Using Pencil Beam Scanning Proton Therapy

Emory Proton Therapy Center, Atlanta

ReclutandoFase 3

Edades de 19 en adelante · Mujeres · Actualizado el 29 sept 2026 · NCT05856773

Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

Clinical Trial Site, Marietta

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 23 sept 2026 · NCT07085767

A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer

Emory University (Data Collection Only), Atlanta

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 9 sept 2026 · NCT05570253

Toci +/- SOC Chemo for Metastatic Triple Negative and ER-positive, HER2-negative Breast Cancers

Emory University, Atlanta

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 3 sept 2026 · NCT05846789

Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.

Winship Cancer Institute of Emory University, Atlanta

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 2 sept 2026 · NCT06072612

A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases

Augusta University, Augusta

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 21 ago 2026 · NCT06764940

Mobile Health Patient Navigation for the Improvement of Screening and the Early Detection of Breast Cancer in Women Accessing Primary Care Clinics in Kenya

Emory University Hospital/Winship Cancer Institute, Atlanta

ReclutandoSe aceptan voluntarios sanos

Edades de 18 en adelante · Todos los sexos · Actualizado el 14 ago 2026 · NCT07764796

FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer

Emory University, Atlanta

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 12 ago 2026 · NCT05304962

Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC

Winship Cancer Institute at Emory University, Atlanta

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 12 ago 2026 · NCT06263543

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

Northside Hospital, Atlanta

ReclutandoFase 2/3

Edades de 18 en adelante · Todos los sexos · Actualizado el 10 ago 2026 · NCT06926868

Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects

City of Hope - Cancer Center Atlanta, Newnan

ReclutandoFase 3

Edades de 18 a 100 · Todos los sexos · Actualizado el 6 ago 2026 · NCT05232916

First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

Winship Cancer Institute, Emory University, Atlanta

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 7 jul 2026 · NCT05768139

A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors

Winship Cancer Institute, Emory University, Atlanta

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 29 jun 2026 · NCT05377996

De ClinicalTrials.gov, datos obtenidos el 15 nov 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.